Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy

被引:12
|
作者
Sircar, Anuvrat [1 ]
Chowdhury, Sayan Mullick [1 ]
Hart, Amber [1 ]
Bell, William Connor [1 ]
Singh, Satishkumar [1 ]
Sehgal, Lalit [1 ]
Epperla, Narendranath [1 ]
机构
[1] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
关键词
diffuse large B-cell lymphoma; mantle cell lymphoma; follicular lymphoma; bone marrow microenvironment; relapse; drug resistance; NON-HODGKIN-LYMPHOMA; PROGRESSION-FREE SURVIVAL; REGULATORY T-CELLS; STEM-CELL; FOLLICULAR LYMPHOMA; OPEN-LABEL; AUTOLOGOUS TRANSPLANTATION; INVESTIGATORS CHOICE; PLUS RITUXIMAB; HIGH NUMBERS;
D O I
10.3390/ijms21030904
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lymphoma, a group of widely prevalent hematological malignancies of lymphocyte origin, has become the focus of significant clinical research due to their high propensity for refractory/relapsed (R/R) disease, leading to poor prognostic outcomes. The complex molecular circuitry in lymphomas, especially in the aggressive phenotypes, has made it difficult to find a therapeutic option that can salvage R/R disease. Furthermore, the association of lymphomas with the Bone Marrow (BM) microenvironment has been found to portend worse outcomes in terms of heightened chances of relapse and acquired resistance to chemotherapy. This review assesses the current therapy options in three distinct types of lymphomas: diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. It also explores the role of the BM tumor microenvironment as a secure 'niche' for lymphoma cells to grow, proliferate and survive. It further evaluates potential mechanisms through which the tumor cells can establish molecular connections with the BM cells to provide pro-tumor benefits, and discusses putative therapeutic strategies for disrupting the BM-lymphoma cell communication.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] The challenge of the microenvironment in B-cell lymphomas
    Coupland, Sarah E.
    HISTOPATHOLOGY, 2011, 58 (01) : 69 - 80
  • [2] CAR T cell therapy for B-cell lymphomas
    Chavez, Julio C.
    Locke, Frederick L.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (02) : 135 - 146
  • [3] Ibrutinib in B-cell Lymphomas
    Maddocks, Kami
    Blum, Kristie A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (02) : 226 - 237
  • [4] Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas
    Palacio, C
    Acebedo, G
    Navarrete, M
    Ruiz-Marcellán, C
    Sanchez, C
    Blanco, A
    López, A
    HAEMATOLOGICA, 2001, 86 (09) : 934 - 940
  • [5] Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
    Mulder, Tom A.
    Wahlin, Bjorn E.
    Osterborg, Anders
    Palma, Marzia
    CANCERS, 2019, 11 (07)
  • [6] Novel Immunotherapies for B-Cell Lymphomas and Leukemias
    Tees, Michael T.
    Sokol, Lubomir
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (05) : E1157 - E1181
  • [7] Ibrutinib in B-cell Lymphomas
    Kami Maddocks
    Kristie A. Blum
    Current Treatment Options in Oncology, 2014, 15 : 226 - 237
  • [8] Aggressive B-cell lymphomas with a primary bone marrow presentation
    Zamo, Alberto
    Johnston, Peter
    Attygalle, Ayoma D.
    Laurent, Camille
    Arber, Daniel A.
    Fend, Falko
    HISTOPATHOLOGY, 2020, 77 (03) : 369 - 379
  • [9] MicroRNA Expression Profile in Bone Marrow and Lymph Nodes in B-Cell Lymphomas
    Veryaskina, Yuliya
    Titov, Sergei
    Kovynev, Igor
    Pospelova, Tatiana
    Fyodorova, Sofya
    Shebunyaeva, Yana Yu.
    Sumenkova, Dina
    Zhimulev, Igor
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [10] Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment
    Ghia, P.
    Nadel, B.
    Sander, B.
    Stamatopoulos, K.
    Stevenson, F. K.
    JOURNAL OF INTERNAL MEDICINE, 2017, 282 (05) : 395 - 414